Fiscal Period | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Period End Date | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
Net Income/ Starting Line | 569.19 | 868.45 | 1,441.25 | 1,382.48 |
Depreciation/ Depletion | 630.81 | 611.27 | 486.72 | 443.55 |
Non- Cash Items | 379.00 | 860.70 | 300.39 | 201.26 |
Changesin Working Capital | -2,036.20 | -1,714.35 | -1,119.70 | -896.08 |
Cashfrom Operating Activities | -457.20 | 626.06 | 1,108.65 | 1,131.21 |
Capital Expenditures | -914.88 | -607.76 | -790.12 | -774.76 |
Other Investing Cash Flow Items Total | 5,475.77 | 79.27 | 456.84 | 99.52 |
Cashfrom Investing Activities | 4,560.89 | -528.49 | -333.28 | -675.24 |
Financing Cash Flow Items | -516.78 | -464.27 | -307.90 | -293.62 |
Total Cash Dividends Paid | -117.75 | -136.61 | -92.70 | -70.45 |
Issuance( Retirement)of Stock Net | 1.20 | 0.00 | 1,011.85 | - |
Issuance( Retirement)of Debt Net | -3,272.79 | 523.42 | -1,131.75 | -77.71 |
Cashfrom Financing Activities | -3,906.13 | -77.46 | -520.49 | -441.78 |
Foreign Exchange Effects | 17.68 | 12.39 | 17.55 | 13.62 |
Net Changein Cash | 215.24 | 32.50 | 272.43 | 27.82 |
Cash Interest Paid | 516.78 | 311.54 | 250.51 | 293.62 |
Cash Taxes Paid | 1,047.49 | 640.54 | 558.44 | 510.24 |
Glenmark Pharmaceuticals Dividend Glenmark Pharmaceuticals Bonus Glenmark Pharmaceuticals News Glenmark Pharmaceuticals AGM Glenmark Pharmaceuticals Rights Glenmark Pharmaceuticals Splits Glenmark Pharmaceuticals Board Meetings Glenmark Pharmaceuticals Key Metrics Glenmark Pharmaceuticals Shareholdings Glenmark Pharmaceuticals Profit Loss Glenmark Pharmaceuticals Balance Sheet Glenmark Pharmaceuticals Q1 Results Glenmark Pharmaceuticals Q2 Results Glenmark Pharmaceuticals Q3 Results Glenmark Pharmaceuticals Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks